Themis Medicare Board Approves Q3 Results, Appoints Interim CS, Plans Preferential Issue
Themis Medicare reported its Q3 FY26 results. The Board approved the resignation of Company Secretary Mr. Pradeep M. Chandan and appointed Mr. Nagraj Mogaveera as interim CS. The company also approved a preferential issue of convertible equity warrants to promoters, potentially up to 4.99% of shareholding.
The approved preferential issue of warrants and the inter-se transfer of shares in a subsidiary are significant corporate actions that could impact the company's capital structure and promoter group dynamics.
The announcement includes routine financial results, management changes, and a proposal for future fundraising. While the financial results are mixed, the overall impact is neutral as no significant immediate positive or negative events are highlighted.
Themis Medicare Limited announced the outcome of its Board of Directors meeting held on February 13, 2026. The Board approved the Un-Audited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025, along with the Limited Review Report from Statutory Auditors M/s. Krishaan & Co.
The Board also noted the resignation of Mr. Pradeep M. Chandan from the position of Company Secretary, Compliance Officer & Key Managerial Personnel (KMP), effective February 13, 2026, due to other professional commitments. Subsequently, Mr. Nagraj Mogaveera was appointed as the Interim Company Secretary, Compliance Officer & KMP, effective February 14, 2026. Mr. Mogaveera is a qualified Company Secretary with 8 years of experience in company secretarial and corporate governance matters.
Furthermore, the Board approved a proposal for the issuance of convertible equity warrants to Promoter/Promoter Groups via preferential allotment, subject to regulatory and shareholder approvals. A Preferential Issue Committee has been formed to finalize the terms. The issue represents up to 4.99% of total shareholding, equivalent to 45,95,795 equity shares, with the total amount to be decided later.
Additionally, the Board approved an inter-se transfer of up to 3% of the paid-up equity share capital of Gujarat Themis Biosyn Limited (GTBL) held by Themis Medicare Limited, to another Promoter or Promoter Group at prevailing market prices. This is an internal transfer within the Promoter/Promoter Group and will not alter the overall control or shareholding.
What to do with a filing like this
Themis Medicare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Themis Medicare Limited. Read the original for the full detail.